[Icodextrin as first treatment: reasons to be optimistic].
Rivera
M
M
Servicio de Nefrología, Hospital Ramón y Cajal, Madrid, Spain. mriverago@gmail.com
D001692:Biological Transport; D001810:Blood Volume / Q000187:drug effects; D015314:Dialysis Solutions / Q000627:therapeutic use*; D004198:Disease Susceptibility; D005260:Female; D005936:Glucans / Q000627:therapeutic use*; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077607:Icodextrin; D008297:Male; D008970:Molecular Weight; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000379:methods; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods; D010537:Peritoneum / Q000098:blood supply / Q000502:physiology; D010538:Peritonitis / Q000209:etiology / Q000517:prevention & control; D014462:Ultrafiltration
D015314:Dialysis Solutions; D005936:Glucans; D000077607:Icodextrin; D005947:Glucose